

TABLE OF CONTENTS

Abstract	iii
List of Figures	viii
List of Tables	x
CHAPTER 1	11
1.1 Cancer overview	11
1.2 Causative agents in cancer	11
1.2.1 Insensitivity to antigrowth signals	12
1.2.2 Evasion of apoptosis	13
1.2.3 Limitless replicative potential	14
1.2.4 Sustained angiogenesis	14
1.2.5 Tissue invasion and metastasis	15
1.2.6 Self sufficiency of growth signals	15
1.3 Epidermal growth factor receptor (EGFR)	17
1.3.1 Molecular description of EGFR	17
1.3.2 EGFR signalling pathways	18
1.3.3 The mitogen-activated protein kinase pathway (MAPK)	18
1.3.4 Phosphatidylinositol 3- kinase cascade	19
1.3.5 Alternative EGFR activation pathways	20
1.4 General characteristics of oesophageal cancer in humans	20
1.4.1 Adenocarcinoma	21
1.4.2 Human oesophageal squamous cell carcinoma (HOSCC)	21
1.4.3 Epidemiology of HOSCC	22
1.4.4 Molecular characteristics of HOSCC	22
1.5 Molecular therapeutics in cancer	23
1.5.1 Antibodies	24
1.5.2 Antisense	24
1.5.3 Tyrosine kinase inhibitors	25
1.6 Molecular therapies targeting EGFR	25
1.7 RNA interference	26
1.8 Exploiting the RNAi pathway.	27
1.9 Objectives	30
1.10 Aims	30
Chapter 2	31
2.1 Design and selection of RNA's to be used for knockdown	31
2.2 Small interfering and short hairpin RNAs (siRNA and shRNA)	31
2.3 siRNA/ shRNA design	32
2.4 Materials and methods	33
2.4.1 siRNA selection	33
2.4.2 shRNA design	34
2.4.3 shRNA synthesis:	35
2.4.4 Verification of complete shRNA expression cassette	36
2.5 Results	37

2.5.1	Modification of siRNAs to shRNAs	38
2.5.2	Verification of the shRNAs cassette sequences	41
2.6	Discussion	43
CHAPTER 3		46
3.1	Construction and validation of reporter systems	46
3.2	siRNA/shRNA target efficacy reporter system	46
3.3	Reporter system description	47
3.4	Materials and methods	47
3.4.1	Design of the shRNA efficacy reporter system	47
3.4.2	Construction of the shRNA efficacy reporter system	48
3.4.3	Plasmid preparation for shRNA efficacy reporter system	48
3.4.4	Ligation of 3xEGFR target into the psiCHECK and pCieGFP plasmid	49
3.4.5	Transformation of Escherichia coli DH5 α	49
3.4.6	Confirmation of insert	50
3.5	Results	51
3.6	Discussion	54
CHAPTER 4		57
4.1	EGFR shRNAs knockdown efficiency assay	57
4.1.1	psiCHECK 2.2 dual luciferase reporter system	57
4.1.2	pCieGFP reporter system	58
4.2	Materials and methods	59
4.2.1	Mammalian transfection plasmid description	59
4.2.2	Suitable DNA plasmid isolation for mammalian cell transfection	59
4.2.3	DNA Quantification	60
4.2.4	Mammalian cell culture and transfection	60
4.2.5	Dual luciferase assay	61
4.2.6	pCieGFP EGFR shRNA efficiency reporter system	62
4.3	Results	62
4.3.1	psiCHECK dual luciferase reporter system	62
4.3.2	pCieGFP 3 x EGFR target reporter system	64
4.4	Discussion	70
CHAPTER 5		72
5.1	The potential use of RNAi in cancer therapy	72
5.2	Knockdown of EGFR in HOSCC	72
5.3	Materials and methods	73
5.3.1	HOSCC cell culture and transfection	73
5.3.2	Whole cell extraction	74
5.3.3	Protein estimation	74
5.3.4	SDS-PAGE	75
5.3.5	Western Blotting	75
5.3.6	Densitometry	76
5.4	Results	76
5.4.1	Knockdown of endogenous expressed EGFR	78
5.4.2	Estimation of transfection efficiency	81
5.5	Discussion	83

CHAPTER 6	88
6.1 General discussion	88
6.2 Knockdown of endogeneously over expressed EGFR	88
6.3 Vision for the future	90
6.3.1 Avenues for Exploration	90
6.3.2 Consideration for clinical application	91
6.4 Conclusion	91
References:	92
APPENDIX	100
Tissue culture	100
Protein estimation	101
Sample preparation for SDS-PAGE	102
SDS-PAGE	102
Western Blot	103